Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wierda, W. G.
Right arrow Articles by Kipps, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wierda, W. G.
Right arrow Articles by Kipps, T. J.
Related Collections
Right arrow Plenary Papers
Right arrow Clinical Trials and Observations
Right arrow Gene Therapy
Right arrow Neoplasia
Right arrowRelated Letter in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Next Article next article arrow

Blood, 1 November 2000, Vol. 96, No. 9, pp. 2917-2924

PLENARY PAPER

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia

William G. Wierda, Mark J. Cantwell, Sandra J. Woods, Laura Z. Rassenti, Charles E. Prussak, and Thomas J. Kipps

From the Division of Hematology/Oncology, Department of Medicine, and the UCSD Human Gene Therapy Program, University of California-San Diego, La Jolla, CA; Immunogenex, Inc, La Jolla, CA; and Molecular Medicine/LLC, UCSD, La Jolla, CA.

Chronic lymphocytic leukemia (CLL) cells can be made to express recombinant CD40-ligand (CD154) by transduction with a replication-defective adenovirus vector (Ad-CD154). Ad-CD154-transduced and bystander leukemia cells become highly effective antigen-presenting cells that can induce CLL-specific autologous cytotoxic T lymphocytes in vitro. This study investigated the immunologic and clinical responses to infusion of autologous Ad-CD154-CLL cells in patients with CLL. After a one-time bolus infusion of autologous Ad-CD154-transduced leukemia cells, there was increased or de novo expression of immune accessory molecules on bystander, noninfected CLL cells in vivo. Treated patients also developed high plasma levels of interleukin-12 and interferon-gamma , the magnitudes of which corresponded to absolute blood CD4+ T-cell counts before therapy. On average, patients experienced a greater than 240% increase in absolute blood T-cell counts within 1 to 4 weeks of treatment. Moreover, treatment increased the numbers of leukemia-specific T cells, demonstrated by autologous ELISPOT assay and mixed lymphocyte reactions. These biologic effects were associated with reductions in leukemia cell counts and lymph node size. Treatment did not induce autoimmune thrombocytopenia or hemolytic anemia and no dose-limiting toxicity was observed. This approach may provide a novel and effective form of gene therapy for patients with this disease.

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Letter in Blood Online:

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia
Gabriele Anether, Ingrid Marschitz, Inge Tinhofer, and Richard Greil
Blood 2002 99: 722-723. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 GutHome page
S Serba, J Schmidt, N Wentzensen, E Ryschich, and A Marten
Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma
Gut, March 1, 2008; 57(3): 344 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Fukuda, L. Chen, T. Endo, L. Tang, D. Lu, J. E. Castro, G. F. Widhopf II, L. Z. Rassenti, M. J. Cantwell, C. E. Prussak, et al.
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a
PNAS, February 26, 2008; 105(8): 3047 - 3052.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood, October 15, 2007; 110(8): 2811 - 2818.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Liu, A. Guardino, L. Chinsangaram, M. J. Goldstein, D. Panicali, and R. Levy
Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand
Cancer Res., July 15, 2007; 67(14): 7037 - 7044.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. H. Vonderheide
Prospect of Targeting the CD40 Pathway for Cancer Therapy
Clin. Cancer Res., February 15, 2007; 13(4): 1083 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology, January 1, 2007; 2007(1): 243 - 249.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, et al.
T lymphocytes redirected against the {kappa} light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Blood, December 1, 2006; 108(12): 3890 - 3897.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Dicker, A. P. Kater, C. E. Prada, T. Fukuda, J. E. Castro, G. Sun, J. Y. Wang, and T. J. Kipps
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
Blood, November 15, 2006; 108(10): 3450 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. de Totero, R. Meazza, S. Zupo, G. Cutrona, S. Matis, M. Colombo, E. Balleari, I. Pierri, M. Fabbi, M. Capaia, et al.
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells
Blood, May 1, 2006; 107(9): 3708 - 3715.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
Blood, February 15, 2006; 107(4): 1332 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology, January 1, 2006; 2006(1): 285 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. MESSMER and T. J. KIPPS
CD154 Gene Therapy for Human B-Cell Malignancies
Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
J. C. Fratantoni, L. Li, L. N. Liu, M. V. Peshwa, M. Brenner, E. Yvon, G. Carrum, and E. Biagi
A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 450 - 450.
[Abstract]

Home page
 BloodHome page
C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
Blood, November 15, 2005; 106(10): 3515 - 3523.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner
Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells
Blood, November 1, 2005; 106(9): 3223 - 3226.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Biagi, R. Rousseau, E. Yvon, M. Schwartz, G. Dotti, A. Foster, D. Havlik-Cooper, B. Grilley, A. Gee, K. Baker, et al.
Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res., October 1, 2005; 11(19): 6916 - 6923.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. P. Kater, F. Dicker, M. Mangiola, K. Welsh, R. Houghten, J. Ostresh, A. Nefzi, J. C. Reed, C. Pinilla, and T. J. Kipps
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis
Blood, September 1, 2005; 106(5): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Dicker, A. P. Kater, T. Fukuda, and T. J. Kipps
Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
Blood, April 15, 2005; 105(8): 3193 - 3198.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Biagi, G. Dotti, E. Yvon, E. Lee, M. Pule, S. Vigouroux, S. Gottschalk, U. Popat, R. Rousseau, and M. Brenner
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes
Blood, March 15, 2005; 105(6): 2436 - 2442.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Bonyhadi, M. Frohlich, A. Rasmussen, C. Ferrand, L. Grosmaire, E. Robinet, J. Leis, R. T. Maziarz, P. Tiberghien, and R. J. Berenson
In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia
J. Immunol., February 15, 2005; 174(4): 2366 - 2375.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al.
Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis
J. Immunol., January 1, 2005; 174(1): 41 - 50.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. Hallek and On Behalf Of The German CLL Study Group
Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
Hematology, January 1, 2005; 2005(1): 285 - 291.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Gricks, D. Zahrieh, A. J. Zauls, G. Gorgun, D. Drandi, K. Mauerer, D. Neuberg, and J. G. Gribben
Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells
Blood, December 15, 2004; 104(13): 4002 - 4009.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Watson, G. Y. Zhang, M. Sartor, and S. I. Alexander
"Pruning" of Alloreactive CD4+ T Cells Using 5- (and 6-)Carboxyfluorescein Diacetate Succinimidyl Ester Prolongs Skin Allograft Survival
J. Immunol., December 1, 2004; 173(11): 6574 - 6582.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
C.-H. Lin, T. Kerkau, C. Guntermann, M. Trischler, N. Beyersdorf, Y. Scheuring, H.-P. Tony, C. Kneitz, M. Wilhelm, P. Mueller, et al.
Superagonistic Anti-CD28 Antibody TGN1412 as a Potential Immunotherapeutic for the Treatment of B Cell Chronic Lymphocytic Leukemia.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2519 - 2519.
[Abstract]

Home page
 Ann OncolHome page
M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben
CD40 activation: potential for specific immunotherapy in B-CLL
Ann. Onc., June 1, 2004; 15(6): 853 - 857.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello
Immunotherapeutic Approaches for Hematologic Malignancies
Hematology, January 1, 2004; 2004(1): 337 - 353.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Rieger and T. J. Kipps
CpG Oligodeoxynucleotides Enhance the Capacity of Adenovirus-mediated CD154 Gene Transfer to Generate Effective B-Cell Lymphoma Vaccines
Cancer Res., July 15, 2003; 63(14): 4128 - 4135.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. E. Battle, W. G. Wierda, L. Z. Rassenti, D. Zahrieh, D. Neuberg, T. J. Kipps, and D. A. Frank
In Vivo Activation of Signal Transducer and Activator of Transcription 1 after CD154 Gene Therapy for Chronic Lymphocytic Leukemia Is Associated with Clinical and Immunologic Response
Clin. Cancer Res., June 1, 2003; 9(6): 2166 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Gitelson, C. Hammond, J. Mena, M. Lorenzo, R. Buckstein, N. L. Berinstein, K. Imrie, and D. E. Spaner
Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines
Clin. Cancer Res., May 1, 2003; 9(5): 1656 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Briones, J. M. Timmerman, D. L. Panicalli, and R. Levy
Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules
J Natl Cancer Inst, April 2, 2003; 95(7): 548 - 555.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Bovia, P. Salmon, T. Matthes, K. Kvell, T. H. Nguyen, C. Werner-Favre, M. Barnet, M. Nagy, F. Leuba, J.-F. Arrighi, et al.
Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors
Blood, March 1, 2003; 101(5): 1727 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Granziero, P. Circosta, C. Scielzo, E. Frisaldi, S. Stella, M. Geuna, S. Giordano, P. Ghia, and F. Caligaris-Cappio
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes
Blood, March 1, 2003; 101(5): 1962 - 1969.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Linderoth, M. Jerkeman, E. Cavallin-Stahl, S. Kvaloy, and E. Torlakovic
Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study
Clin. Cancer Res., February 1, 2003; 9(2): 722 - 728.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.-R. Rezvany, M. Jeddi-Tehrani, H. Wigzell, A. Osterborg, and H. Mellstedt
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
Blood, February 1, 2003; 101(3): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology, January 1, 2003; 2003(1): 153 - 175.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-M. Wendtner, D. M. Kofler, H. D. Theiss, C. Kurzeder, R. Buhmann, C. Schweighofer, L. Perabo, S. Danhauser-Riedl, J. Baumert, W. Hiddemann, et al.
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors
Blood, August 13, 2002; 100(5): 1655 - 1661.
[Abstract] [Full Text] [PDF]